^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MAGEA4 overexpression

    i
    Other names: MAGEA4, CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336, Melanoma antigen family A, 4
    Entrez ID:
    4103
    Related biomarkers:
    Expression
    Others
    2ms
    Long non-coding RNA MAGEA4-AS1 binding to p53 enhances MK2 signaling pathway and promotes the proliferation and metastasis of oral squamous cell carcinoma. (PubMed, Funct Integr Genomics)
    In conclusion, MAGEA4-AS1-p53 complexes bind to MK2 promoter, enhancing the transcription of MK2 and activating the downstream signaling pathways, consequently promoting the proliferation and metastasis of OSCC cells. MAGEA4-AS1 may serve as a diagnostic marker and therapeutic target for OSCC patients.
    Journal
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    TP53 expression • MAGEA4 expression • MAGEA4 overexpression
    7ms
    Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma. (PubMed, Sci Rep)
    Further analysis signified that the expression of MAGEA3 mRNA was positive correlation with neutrophil, macrophages M2, dendritic cells resting, and eosinophilic, but negatively correlated with B cells, plasma cells, CD8 + T cells, CD4 + T cells, Th17 cells, macrophages and dendritic cells. Collectively, our results suggested that the MAGEA3 expression in mRNA and protein were upregulated in LUAD, and MAGEA3 could be used as a diagnostic biomarker and immunotherapy target for LUAD patients.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MAGEA4 (Melanoma antigen family A, 4) • MAGEA3 (MAGE Family Member A3)
    |
    MAGEA3 overexpression • MAGEA4 overexpression
    11ms
    IMA401 TCER® in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Immatics Biotechnologies GmbH | Phase classification: P1a/1b --> P1
    Phase classification
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    MAGEA4 expression • MAGEA4 overexpression
    |
    IMA401
    1year
    ENROLLMENT OF PEDIATRIC PARTICIPANTS WITH MAGE-A4-POSITIVE SOLID TUMORS IN A PHASE 1/2, OPEN-LABEL, BASKET TRIAL OF AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL") (CTOS 2023)
    Lymphodepleting chemotherapy consisting of fludarabine (30 mg/m^2/day for 4 days) and cyclophosphamide (600 mg/m^2/day for 3 days) will be administered beginning one week prior to afami-cel infusion... N/A. Submitting under Trials in Progress.
    Clinical • P1/2 data • IO biomarker • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression • MAGEA4 overexpression
    |
    cyclophosphamide • fludarabine IV • Tecelra (afamitresgene autoleucel)
    over1year
    Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. (PubMed, Mol Oncol)
    The current study provides a comprehensive evaluation of CTAs, and suggests that their association with immune cells may indicate in situ immunogenic effects. The findings support the rationale to harness CTAs as targets for immunotherapy.
    Journal • IO biomarker
    |
    CD163 (CD163 Molecule) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • FOXP3 (Forkhead Box P3) • MAGEB2 (MAGE Family Member B2) • MAGEC2 (MAGE Family Member C2)
    |
    MAGEA4 expression • MAGEA4 overexpression • FOXP3 expression